Physician profile
Danielle M Ratazak
NPI 1023353844
$1,552.27
in general payments reported to CMS, 2019-2025
25 companies · $121 in 2025
The $121 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $125 · 2022: $408 · 2023: $373 · 2024: $525 · 2025: $121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,019.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,019.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $334.79 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Otsuka America Pharmaceutical, INC. | $296.07 | 2022-2024 | Rexulti |
| Nestle Healthcare Nutrition INC. | $102.92 | 2021-2023 | |
| Novo Nordisk INC | $90.18 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $89.77 | 2021-2023 | |
| Aimmune Therapeutics, INC. | $69.17 | 2024 | |
| Merck Sharp & Dohme LLC | $67.22 | 2024 | Gardasil, Gardasil 9, Capvaxive |
| Medtronic, INC. | $67.13 | 2021-2022 | |
| Gilead Sciences, INC. | $60.79 | 2023-2024 | |
| Lilly USA, LLC | $52.98 | 2023-2024 | Mounjaro |
| Organon LLC | $36.95 | 2023 | Nexplanon |
| E.R. Squibb & Sons, L.L.C. | $32.02 | 2024-2025 | Eliquis |
| Sanofi-Aventis U.S. LLC | $30.47 | 2021-2022 | |
| Abbvie INC. | $29.38 | 2023 | |
| Ardelyx, INC. | $26.16 | 2024 | Ibsrela |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $23.02 | 2024 | Uzedy |
| Biohaven Pharmaceutical Holding Company LTD. | $22.18 | 2022 | |
| Sumitomo Pharma America, INC. | $19.50 | 2023 | Gemtesa |
| Neurocrine Biosciences, INC. | $17.77 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $14.99 | 2025 | Zoryve |
| Hologic Sales and Service, LLC | $14.98 | 2024 | Aptima |
| Phadia US INC. | $14.68 | 2021 | |
| Inspire Medical Systems, INC. | $14.03 | 2024 | Inspire |
| Amgen INC. | $12.88 | 2023 | Prolia, Evenity |
| Philips North America LLC | $12.24 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Ratazak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.